3 Big Pharmas Expecting a Softer 2019

Johnson & Johnson (NYSE: JNJ) kicked off this earnings season with a grim outlook for its pharmaceutical business, and it looks like the trouble has spread to its big pharma peers. More recently, AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) told investors not to expect a great deal of sales growth in 2019.